University of Turin

About: University of Turin is a education organization based out in Turin, Piemonte, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 29607 authors who have published 77952 publications receiving 2480900 citations. The organization is also known as: Universita degli Studi di Torino & Università degli Studi di Torino.

XAFS, IR, and UV−Vis Study of the CuI Environment in CuI-ZSM-5

Abstract: XAFS, IR, and UV−vis (diffuse reflectance and photoluminescence) spectroscopies have been employed to investigate the local environment of CuI in CuI-ZSM-5 prepared by gas phase reaction of H-ZSM-5 (SiO2/Al2O3 = 90−50) with CuCl The measurements confirm that the absolutely predominant copper species formed with this procedure are CuI:Cu species in other oxidation states are less than 1% Direct proof of the absence of both unreacted CuCl microaggregates and of copper clusters in the zeolite channels is also given CuI-ZSM-5 prepared in this way represents a model solid for investigating the structure of isolated CuI sites in zeolites EXAFS analysis reveal that, in vacuum conditions, Cu+ cations are surrounded by 25 ± 03 oxygens at 200 ± 002 A The combined use of EXAFS, IR, and photoluminescence UV−vis spectroscopies and computer graphic simulations allows to infer that Cu+ ions in CuI-ZSM-5 are located in two families of sites, indicated as I and II, (site II having the highest coordinative unsatur

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

Abstract: A metastatic cancer develops by accumulation of mutations in genes that control growth, survival and spreading. The latter genes have not yet been identified. In lymph node metastases of head and neck squamous cell carcinomas (HNSCC), we found mutations in the MET oncogene, which encodes the tyrosine kinase receptor for Scatter Factor, a cytokine that stimulates epithelial cell motility and invasiveness during embryogenesis and tissue remodeling. We identified two somatic mutations: the Y1230C, known as a MET germline mutation which predisposes to hereditary renal cell carcinoma, and the Y1235D that is novel and changes a critical tyrosine, known to regulate MET kinase activity. The mutated MET receptors are constitutively active and confer an invasive phenotype to transfected cells. Interestingly, cells carrying the MET mutations are selected during metastatic spread: transcripts of the mutant alleles are highly represented in metastases, but barely detectable in primary tumors. These data indicate that cells expressing mutant MET undergo clonal expansion during HNSCC progression and suggest that MET might be one of the long sought oncogenes controlling progression of primary cancers to metastasis.

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Abstract: Personalized cancer medicine is based on the concept that targeted therapies are effective on subsets of patients whose tumors carry specific molecular alterations. Several mammalian target of rapamycin (mTOR) inhibitors are in preclinical or clinical trials for cancers, but the molecular basis of sensitivity or resistance to these inhibitors among patients is largely unknown. Here we have identified oncogenic variants of phosphoinositide-3-kinase, catalytic, α polypeptide (PIK3CA) and KRAS as determinants of response to the mTOR inhibitor everolimus. Human cancer cells carrying alterations in the PI3K pathway were responsive to everolimus, both in vitro and in vivo, except when KRAS mutations occurred concomitantly or were exogenously introduced. In human cancer cells with mutations in both PIK3CA and KRAS, genetic ablation of mutant KRAS reinstated response to the drug. Consistent with these data, PIK3CA mutant cells, but not KRAS mutant cells, displayed everolimus-sensitive translation. Importantly, in a cohort of metastatic cancer patients, the presence of oncogenic KRAS mutations was associated with lack of benefit after everolimus therapy. Thus, our results demonstrate that alterations in the KRAS and PIK3CA genes may represent biomarkers to optimize treatment of patients with mTOR inhibitors.